DEF: Lunai Bioworks Seeks Stockholder Approval for Reverse Stock Split

Lunai Bioworks, Inc. is holding a special meeting on May 4, 2026, to seek stockholder approval for a reverse stock split aimed at maintaining its Nasdaq listing.

Summary

• Lunai Bioworks, Inc. is convening a special meeting of stockholders on May 4, 2026, to vote on two proposals.
• The primary proposal (Proposal 1) seeks approval to amend the company's Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio between 1-for-3 and 1-for-30, with the exact ratio to be determined by the Board of Directors.
• The company's main objective for the reverse stock split is to increase the per-share trading price of its common stock to comply with Nasdaq's minimum bid price requirement of $1.00 and avoid delisting.
• The company received a delisting notice from Nasdaq on February 6, 2026, due to non-compliance with the minimum bid price rule, despite a previous reverse stock split on September 30, 2025.
• A hearing was held on March 26, 2026, and the delisting action is stayed pending the Nasdaq Hearings Panel's decision.
• The secondary proposal (Proposal 2) is to approve the adjournment of the Special Meeting if necessary to solicit additional proxies for Proposal 1.
• The record date for determining stockholders entitled to vote is April 10, 2026, with 36,271,119 shares of common stock outstanding.
• The proxy materials are expected to be made available to stockholders on or about April 13, 2026.
• Fractional shares resulting from the reverse stock split will be rounded up to the next whole share, with no cash payment made for fractional interests.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, as it highlights a critical compliance issue (potential delisting) that necessitates a reverse stock split, a measure often viewed unfavorably by investors due to its association with struggling companies.

Positives

• The proposed reverse stock split aims to increase the per-share trading price, potentially improving marketability and liquidity.
• The action is intended to help the company maintain its listing on The Nasdaq Stock Market LLC.
• The Board believes the reverse stock split could make the stock more attractive to a broader range of investors.
• The company expects the reverse stock split to enhance its ability to access capital markets and attract/retain employees receiving equity compensation.
• Fractional shares will be rounded up to the next whole share, avoiding cash payments and simplifying administration.

Negatives

• The company is currently facing a delisting determination from Nasdaq due to not meeting the minimum bid price requirement.
• The reverse stock split may not achieve its intended objectives, including maintaining the Nasdaq listing or increasing the stock price.
• The reverse stock split could reduce the liquidity of the common stock if the market price does not increase proportionally.
• The increase in authorized but unissued shares could be dilutive to existing stockholders if issued in the future.
• The voting standard for Proposal 1 could default to a higher threshold (majority of all outstanding shares) if the stock is delisted before the amendment becomes effective, making approval more difficult.

Risks

• The Reverse Stock Split may not increase the price of our Common Stock in proportion to the reduction in the number of outstanding shares, or at all.
• Even if the Reverse Stock Split initially increases the market price of our Common Stock, the market price may decline thereafter, and we may remain unable to satisfy Nasdaq's continued listing requirements.
• The Reverse Stock Split may reduce the liquidity of our Common Stock because fewer shares will be outstanding after the Reverse Stock Split, particularly if the market price does not increase as a result of the Reverse Stock Split.
• The effective increase in the number of authorized but unissued shares of Common Stock could be dilutive to existing stockholders if those shares are issued in the future.
• The Company may remain subject to delisting if it fails to satisfy other continued listing requirements, including stockholder distribution requirements, market value thresholds or Nasdaq's discretionary authority under its qualitative listing standards.
• If the Company is delisted from Nasdaq, its Common Stock may trade on the over-the-counter market, which could adversely affect liquidity, market price and investor interest.

Future Outlook

The company is seeking stockholder approval for a reverse stock split to increase its per-share trading price and maintain its Nasdaq listing. The exact ratio will be determined by the Board of Directors within a range of 1-for-3 to 1-for-30. The effectiveness of the reverse stock split is contingent on the Board's decision and the company's Nasdaq listing status.

Management Comments

• The Board believes that obtaining stockholder approval of a range of ratios provides the Board with flexibility to implement the Reverse Stock Split in a manner designed to maximize the anticipated benefits of the Reverse Stock Split in light of then-current market conditions, the trading price of our Common Stock and Nasdaq listing considerations.
• The Board believes that effecting the Reverse Stock Split may also improve the marketability and liquidity of our Common Stock, make our Common Stock more attractive to a broader range of institutional and other investors, and enhance our ability to access the capital markets and to attract and retain employees, directors and service providers who receive equity-based compensation.
• The Board has no current plans, proposals or arrangements to issue any of the additional authorized but unissued shares of Common Stock that would become available as a result of the Reverse Stock Split.
• The Board has no present intent to effect a going private transaction within the meaning of Rule 13e-3 under the Securities Exchange Act of 1934, as amended, and the Reverse Stock Split is not being proposed as the first step in any such transaction.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common strategy for companies facing delisting due to low share prices, particularly in the biotechnology and technology sectors where maintaining exchange listing is crucial for investor confidence and access to capital. Competitors often undertake similar measures to meet exchange requirements.

Legal Proceedings

• The company received a delisting notice from Nasdaq on February 6, 2026, for non-compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
• A hearing before the Nasdaq Hearings Panel was held on March 26, 2026, and the delisting action is stayed pending the Panel's final decision.

Stakeholder Impact

• Shareholders: May experience a change in the per-share price and potentially reduced liquidity if the reverse stock split is not successful in maintaining the Nasdaq listing. The number of shares held will decrease, but percentage ownership will remain the same unless fractional shares are involved. Increased authorized shares could lead to future dilution.
• Employees: May benefit from improved stock marketability and retention if equity compensation becomes more attractive.
• Investors: May view the reverse stock split as a sign of financial distress, potentially impacting investment decisions.
• Nasdaq: The company is seeking to comply with Nasdaq's continued listing requirements.

Next Steps

• Stockholders to vote on Proposal 1 (Reverse Stock Split) and Proposal 2 (Adjournment Proposal) at the Special Meeting on May 4, 2026.
• If Proposal 1 is approved, the Board of Directors will determine the exact reverse stock split ratio and file the Certificate of Amendment.
• The company will announce the final voting results in a Form 8-K filed with the SEC within four business days after the Special Meeting.

Key Dates

Recommendation

The filing indicates a critical need for a reverse stock split to maintain Nasdaq listing, which is a significant concern. While the split aims to address this, its success is not guaranteed, and it carries risks of reduced liquidity and potential future dilution. Given the uncertainty surrounding the Nasdaq hearing outcome and the effectiveness of the split, a 'hold' recommendation is prudent, pending further clarity on the company's listing status and market reaction.

Keywords

reverse stock split, Lunai Bioworks, LNAI, Nasdaq listing, proxy statement, special meeting, stockholder approval, certificate of incorporation amendment, delisting, common stock